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Abstract 
Aim: In premenopausal women, hyper-androgenicity is associated with central 
obesity and an increased cardiovascular risk. We investigated the effects of 
dydrogesterone (DYD)(a non-androgenic progestogen) and norethisterone 
(NET)(an androgenic progestogen) on lipoprotein lipase (LPL), hormone-sensitive 
lipase (HSL) and glycerol release in adipocytes isolated from subcutaneous 
abdominal adipose tissue. Methods: Adipose tissue was obtained from 12 non-
diabetic women, mean age 51 years (range 37-78) and mean BMI 25.4kg/m2 (range 
20.3-26.4). Adipocytes were treated with increasing doses of DYD and NET for 48 
hours prior to protein extraction. Effects on lipogenesis and lipolysis were assessed 
using western blotting to determine the expression of key enzymes, LPL (56kDa) 
and HSL (84kDa) respectively. Measurement of glycerol release into the medium 
provided an assessment of lipolytic activity. Results: Expression of LPL was 
increased by DYD and NET (mean protein expression relative to control ± SEM); 
with greatest effect at 10-8M for DYD: 2.32±0.51(p<0.01) and 10-8M for NET: 
2.06±0.19(p<0.01). In contrast, HSL expression was reduced by all concentrations 
of DYD, with maximal effect at 10-9M: 0.49±0.02(p<0.001). NET reduced HSL 
expression at all concentrations from 10-9M: 0.62±0.06(p<0.001) to 10-7M: 
0.69±0.08(p<0.001). Glycerol measurements supported the HSL expression 
studies(p>0.05). Conclusions: DYD and NET significantly increased LPL 
expression relative to control whilst significantly reducing HSL expression. At the 
concentrations studied, similar effects were observed with the androgenic NET and 
the non-androgenic DYD despite differing effects on the lipid profile when taken 
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in combination with estrogen. Further work in this area may improve knowledge 
about the effects of different progestogens on body fat distribution and enable 
progestogen use to be tailored to the individual to achieve maximal benefits. 
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Introduction  
Oral estrogen therapy (ET) is associated with a beneficial reduction in total and low 
density (LDL)-cholesterol and an increase in high density (HDL)-cholesterol, but also a 
potentially deleterious increase in serum triglycerides suggesting increased lipolytic 
activity [1-5]. Recent clinical studies suggest that ET may have beneficial effects on the 
central body fat [6] that is recognised to accumulate following the menopause [7] and 
which is associated with increased cardiovascular risk [8]. Similarly, clinical studies in 
men associate testosterone deficiency with central obesity [9,10], with testosterone 
appearing to reverse this adiposity suggesting that androgen deficiency in men is 
associated with central obesity [11]. In premenopausal women, hyper-androgenicity is 
associated with central obesity [12], which raises concern about the possible androgenic 
effects of the progestogen component of combined estrogen and progestogen therapy 
(EPT).  
Progestogen is required to protect against uterine carcinoma observed in women with an 
intact uterus using unopposed estrogen [13]. Progestogens may reduce the beneficial 
effects of estrogen on the lipid profile but may also be beneficial [14]. The 19-
nortestosterone derivatives e.g. norethisterone (NET) possess androgenic properties, whilst 
the C21 progestogens e.g. dydrogesterone (DYD) are less androgenic [15]. In a pooled 
analysis of oral EPT, DYD did not oppose the adverse rise in triglycerides or the beneficial 
rise in HDL-cholesterol seen with ET. NET induced a net reduction in triglycerides but 
also a net reduction in HDL-cholesterol [14]. Clinical studies examining the effects of EPT 
on body fat distribution have also suggested beneficial effects [6, 16-18]. 
Fat mass is controlled by the processes of lipogenesis and lipolysis, with the key 
regulatory enzymes being lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL) 
respectively. Most animal and human studies of progestogens, in the presence of 
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estrogen, have shown increased adipose tissue LPL activity [19-25], although not all 
progestogens used in EPT have been studied. There is less data on the effects of 
progestogens on lipolysis with no clear overall picture having emerged [21, 24-26].   
Our aim was to investigate effects of a non-androgenic progestogen, DYD, and an 
androgenic progestogen, NET, on lipogenesis and lipolysis in subcutaneous abdominal 
adipocytes isolated from women through measurement of LPL and HSL respectively. In 
addition, we investigated the rate of lipolysis through measurement of the glycerol 
concentration in the media. 
 
Materials and Methods 
Isolation of mature adipocytes 
Subcutaneous abdominal adipose tissue was obtained from 12 non-diabetic subjects 
(mean age 51 years (range 37-78), mean BMI 24.5 kg/m2 (20.3-26.4). Samples were 
obtained during elective surgery in accordance with guidelines from South Birmingham 
ethics committee. Women using glucocorticoids, levothyroxine, oral contraceptives, ET, 
EPT and lipid-lowering therapies were excluded. 
Adipocytes were isolated using previously described methods [27, 28] and cultured in 
phenol red-free Dulbecco’s modified Eagle’s medium (DMEM/F12)(Gibco, UK) with 
penicillin (100U/ml), streptomycin (100μ/ml) and transferrin (5μ/ml)(Sigma, UK). 
Compacted 1ml aliquots of adipocytes (approximately 500,000 cells) were treated with 
DYD (Solvay Pharmaceuticals, UK) and NET (Sigma, UK) from 10-9M to 10-7M and 
maintained for 48 hours. Samples without hormones added were maintained as controls. 
Due to the large number of treatments involved, it was not always possible to obtain 
sufficient material for all of the treatments to be studies in each patient. As previously 
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described, assessment of adipocyte viability, extraction and quantification of protein 
was performed [27, 28]. 
 Analysis of samples 
Equal amounts of protein for each treatment and control (10-50μg) were analysed using 
Western blotting as previously described [27, 28]. Primary antibodies against LPL 
(56kDa)(1 in 5000 with BSA 0.05%; Research Diagnostics Inc, USA) or HSL 
(84kDa)(1 in 500) [29] were used, with anti-mouse and anti-rabbit secondary antibody 
respectively (Binding Site, UK). Chemiluminescent detection was then utilised (ECL+ 
for LPL and ECL for HSL; Amersham Pharmacia Biotech, UK), with quantification of 
radiographs using Windows: Gelbase/Gelblot (UVP Ltd, UK). 
The glycerol concentration in the media samples were analysed in triplicate using a 
commercially available colourimetric method (Randox Laboratories, UK). 
Statistical analysis was undertaken using analysis of variance for the comparison of 
control against treatment samples. 
 
Results 
Effects on LPL protein expression 
All concentrations of DYD increased LPL protein expression, with the maximal effect 
observed at 10-8M; mean protein expression relative to control ± standard error; 
DYD10-8M: 2.32±0.51(p<0.01)(Figure 1). Similarly, all concentrations of NET 
increased LPL protein expression, with the maximal effect at NET10-8M: 2.06±0.19 
(p<0.01)(Figure 1).  
Effects on HSL protein expression  
DYD reduced expression of HSL protein with increasing concentrations, with the 
maximal effect observed at DYD10-9M: 0.49±0.02(p<0.001)(Figure 2). Similarly, HSL 
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protein expression was reduced by NET at all concentrations from NET10-9M: 
0.62±0.06(p<0.001) to NET10-7M: 0.69±0.08(p<0.001)(Figure 2).  
Glycerol release studies 
Lower glycerol concentrations were detected in the medium compared to control from 
10-9M to 10-7M for both DYD and NET (p>0.05) (data not shown). These data are in 
agreement with the HSL protein expression studies. 
 
Discussion 
 
We present the first in vitro evidence that DYD and NET have regulatory effects on 
lipogenesis and lipolysis in subcutaneous abdominal adipocytes isolated from women. 
Addition of DYD and NET increased LPL protein expression and reduced HSL protein 
expression, suggesting increased lipogenesis and reduced lipolysis respectively. These 
results confirm that progestogens may regulate adipose tissue mass through effects on 
the net amount of adipose tissue in the adipocyte. Together with evidence that 
progesterone increases adipocyte number through effects on proliferation and 
differentiation in rats [30, 31], our findings suggest that progesterone has a role in the 
regulation of fat mass. Despite evidence that HT (hormone therapy) does not cause 
weight gain, many women express concern about gain weight when considering HT 
[32]. Further information about effects of EPT on body fat may help alleviate some of 
the fears that women have about weight gain. 
The effects of the progestogens on glycerol release, whilst not statistically significant, 
suggested a trend consistent with the HSL expression studies. The absence of statistical 
significance might be due to increased cell lysis leading to increased glycerol release 
and greater variability in the samples.  
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The protein expression studies are in keeping with studies of adipose tissue in intact 
female rats showing that progesterone alone [19–21], and in combination with estrogen, 
increased LPL activity [19,22]. Few studies have examined the effects of progesterone 
on lipolysis in rats although no effect was seen in intact female rats [21] or 
ovariectomised and adrenalectomised rats [25]. Further work using progesterone both 
alone and with estrogen, in ovariectomised and adrenalectomised rats [25, 33-35], 
concluded that estrogen is required for the effects of progesterone on lipogenesis and 
lipolysis to be seen [25].  In our study, estrogen was not added to the isolated adipocytes 
since the aim was to study the effects of the progestogens alone. The adipocytes had, 
however, been exposed to estrogen prior to isolation since the cells were obtained from 
women and even postmenopausal women are recognised to possess measurable plasma 
and adipose tissue levels of estrogen [36]. 
Previous in vivo human work showed that percutaneous progesterone applied to the 
thigh for 24 hours, during the follicular phase of the menstrual cycle, increased LPL 
activity in femoral adipose tissue [23] in agreement with our findings. Oral 17β-
estradiol (E2), in combination with androgenic progestogens; levonorgestrel or 
sequential medroxyprogesterone acetate, was found to increase LPL activity 
significantly in subcutaneous adipocytes from the femoral area, but not to have 
significant effects in the abdominal area [24]. These results suggest a modulating role 
for progestogens, since alone E2 reduces lipogenesis in adipocytes from subcutaneous 
abdominal [28] and gluteal adipose tissue [39,40]. The combination of E2 and 
levonorgestrel did not significantly alter lipolysis measured by glycerol release [24] 
suggesting that the progestogen may also modulate the effects of E2 on lipolysis since E2 
alone has been shown to increase lipolysis in animal [24, 41-42] and human studies 
[28]. Work using oral ethinyl estradiol (EE) alone, and in combination with NET, gave 
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differing results [26] that might be due to the doses of estrogen used or the different 
systemic potencies of E2 and EE [43].  
In summary, in subcutaneous abdominal adipocytes isolated from women, the 
progestogens increased LPL protein expression and reduced HSL protein expression 
relative to control. Similar effects were observed with androgenic NET and non-
androgenic DYD at the concentrations studied despite the differing effects on the lipid 
profile when each are taken with estrogen as oral EPT [14]. The concentration of 
progestogen in fat following oral administration is not known, however, and may differ 
dramatically to the concentrations used and could also differ with the progestogen. 
Additional information might be obtained through similar studies using lower hormone 
concentrations in this adipose tissue depot and also in other adipose tissue depots. The 
discovery in human adipose tissue of the estrogen receptor (ER) [44], the progesterone 
receptor (PR) and its isoforms (PR-A and PR-B) [45], provides further opportunities to 
determine how sex steroids influence body fat distribution. Consideration is 
increasingly been given to the progestogen chosen for combination with estrogen in HT. 
Additional work in this area may enable the progestogen in EPT to be further tailored to 
the individual woman to optimise effects on both the lipid profile and body fat 
distribution from the perspective of cardiovascular risk.  
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Figure 2  
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Figure Legends 
Figure 1. These graphs show the mean protein expression relative to control for 
(A) dydrogesterone (DYD)(10-9M to 10-7M) (n=4) and (B) norethisterone 
(NET)(10-9M to 10-7M) (n=4) for lipoprotein lipase in isolated subcutaneous 
abdominal adipocytes from women. Values expressed as mean ± standard error, 
with a representative western blot shown for both graphs and p values; *p<0.05, 
**p<0.01.  
 
Figure 2. These graphs show the mean protein expression relative to control for 
(A) dydrogesterone (DYD)(10-9M to 10-7M) (n=6) and (B) norethisterone 
(NET)(10-9M to 10-7M) (n=4) for hormone-sensitive lipase in isolated 
subcutaneous abdominal adipocytes from women. Values expressed as mean ± 
standard error, with a representative western blot shown for both graphs and p 
values; *p<0.05, **p<0.01, ***p<0.001.  
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